{"ticker": {"uuid": "a1506a8d-4307-4bf0-8478-ea7b8415652e", "symbol": "IMRX", "name": "Immuneering Corp", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQQkhoUFlYd0FQSHh4ck9KaExvSkgycmtSVXpyaUU2LXJzanM1ZG4taER3LUFoaGFmN05XMlhJWTBIMkZXZ3JzTFlCTXpVUzhWLVFQeEl2OXN4S0dJRUthVll2UEFRdHF4Q0JoczN5QnB2VnlVaWhlNkdBeWdLOEd1aWp4TmxmV1prdzRJOE16dDRueTRlZFQyVTdkYXlnTnRhT3c?oc=5", "source_name": "Market source", "published_at": "2026-07-15T16:00:05+00:00", "published_display": "15 Jul 2026 16:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering (IMRX) Proxy filing Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTE1feURjOWhkaUhLZlhZOV9qVXVzMDhsOG1TVHNxZVRBTV94UmlNOGVjb2VidVNWeFJwaWNWa3hGNnBjUWs0VnJzUTJkVWlMdl9VUEZ1aDhEdWszaEFoWnM4T2RqU1ZiN1pzaDhaMmV3OE9Pdw?oc=5", "source_name": "Quartr", "published_at": "2026-07-13T21:58:40+00:00", "published_display": "13 Jul 2026 21:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to earnings forward of Immuneering Corporation \u2013 NASDAQ:IMRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNVU9sRUJTTWFkOEdPTldiaFNCOWthVHhBdVdTQmM1YjV4cW1VQjktWDVyWTN0b1JlcTctbHdMdWxxX19zWTNTbTJqT084Wk56UWFJbUY0WWRPOGdVU0E3enN0UTliaDZjUGJvOHRSTkVrOGtTWDBoSDZtUEtQeVFLd2ljRmtCOUFFVDM3bzVtTnlSQnA4bnFRM0pxX01ETXVpQVE?oc=5", "source_name": "TradingView", "published_at": "2026-07-12T19:02:53+00:00", "published_display": "12 Jul 2026 19:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth", "summary": "Immuneering (NASDAQ:IMRX) is an unprofitable company with a strong cash runway of over three years, possessing US$157m in cash against an annual burn of US$50m as of March 2026. The company has reduced its cash burn by 7% over the last year, indicating steady business development", "url": "https://www.sahmcapital.com/news/content/companies-like-immuneering-nasdaqimrx-are-in-a-position-to-invest-in-growth-2026-06-30", "source_name": "Sahm", "published_at": "2026-06-30T15:41:43", "published_display": "30 Jun 2026 15:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Corp. Class A Actuals & Estimates (NASDAQ:IMRX)", "summary": "Immuneering Corporation's stock (IMRX) is currently trading at $4.53, having decreased slightly in the past 24 hours but showing a 57.29% increase over the last year. Analysts have a wide price target range for IMRX, with a maximum estimate of $30.00 and a minimum of $11.00. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-IMRX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:10:51", "published_display": "26 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering CEO Zeskind buys $10,948 in stock By Investing.com", "summary": "Immuneering Corp (NASDAQ:IMRX) CEO Benjamin J. Zeskind recently purchased 2,400 shares of the company's stock for a total of $10,948, bringing his direct holdings to over 2.3 million shares. This insider purchase occurs as the stock trades near $4.60, up significantly over the pa", "url": "https://ca.investing.com/news/stock-market-news/immuneering-ceo-zeskind-buys-10948-in-stock-93CH-4706573", "source_name": "Investing.com Canada", "published_at": "2026-06-25T13:09:32", "published_display": "25 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering CEO Zeskind buys $10,948 in stock", "summary": "Immuneering Corp's CEO, Benjamin J. Zeskind, purchased 2,400 shares of the company's Class A Common Stock for $10,948 on June 23, 2026. This insider transaction comes as the stock trades near $4.60, with InvestingPro analysis suggesting it is undervalued. The company also announc", "url": "https://m.uk.investing.com/news/stock-market-news/immuneering-ceo-zeskind-buys-10948-in-stock-93CH-4743544?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-25T11:10:51", "published_display": "25 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering CEO buys 2,400 shares in open market | IMRX Insider Trading", "summary": "Immuneering Corp. CEO Benjamin J. Zeskind purchased 2,400 shares of Class A Common Stock in an open-market transaction on June 23, 2026, at a weighted average price of $4.5617 per share. This transaction increases his direct holdings to 2,315,252 shares, with an additional 894,92", "url": "https://www.stocktitan.net/sec-filings/IMRX/form-4-immuneering-corp-insider-trading-activity-930bc27b220a.html", "source_name": "Stock Titan", "published_at": "2026-06-25T01:39:31", "published_display": "25 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering (IMRX) CEO buys 2,400 shares in open-market trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOSm9NcS1sOG9zMGhIU1VZcno0MkE1ck5VQWdYSWpaZ0VFVVJ0RnZ2bTJjcGVqZWRoTUd6WGZYVkIyOXYwcHNMY21tNWNOOWNfUzFNVkRYYWY0MzlmR0xoRm0wLUtWREJJSmQ0TC16cFJJSFVNVWdCNDM4bHUzZVhYX0c5dy1LTXhhNDk2TWpyclRmUF96b3FpTE9JU3N5WmY5TDRCeG9YR0ZJTTdKNEQ4?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering (NASDAQ: IMRX) CSO purchases 6,035 shares in open-market trade", "summary": "Immuneering Corp's Chief Scientific Officer, Brett Matthew Hall, purchased 6,035 shares of Class A Common Stock on June 15, 2026, at a weighted average price of $4.15 per share. This open-market transaction increased his direct holdings to 382,531 shares. The trade was executed t", "url": "https://www.stocktitan.net/sec-filings/IMRX/form-4-immuneering-corp-insider-trading-activity-771fda215c13.html", "source_name": "Stock Titan", "published_at": "2026-06-17T04:39:24", "published_display": "17 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New CFO Andrew Gengos joins Immuneering (NASDAQ: IMRX) with equity grant", "summary": "Immuneering Corporation has appointed Andrew Gengos as its new Chief Financial Officer, Treasurer, and principal financial officer, effective on or before July 16, 2026. He will receive an annual base salary of $530,000, a target annual bonus of 40% of his base salary, and an opt", "url": "https://www.stocktitan.net/sec-filings/IMRX/8-k-immuneering-corp-reports-material-event-5784889e26cb.html", "source_name": "Stock Titan", "published_at": "2026-06-16T08:39:17", "published_display": "16 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Names Andrew Gengos as CFO", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immuneering-names-andrew-gengos-cfo-125828979.html", "source_name": "MT Newswires", "published_at": "2026-06-15T12:58:28+00:00", "published_display": "15 Jun 2026 12:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Appoints Andrew Gengos as Chief Financial Officer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immuneering-appoints-andrew-gengos-chief-113000153.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T11:30:00+00:00", "published_display": "15 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Andrew Gengos joins Immuneering as new chief financial officer", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOWTZUM2lUTmFqbWRBemVSUUNuR1QwcG1DdmhGYkxZVzhaZ2lsdHhSYkxSSGZ6QXNqbkx1N3EwNDVOQ1NLZFppSG1uV3N6S3pPRU91bk9sSXlVR3FzaV94bXA4RnFmbG83Q282T0p1WV8wYkZPdm1lcktvcjg0S0l1Wg?oc=5", "source_name": "Traders Union", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Shareholders Approve Directors and Auditor at Meeting", "summary": "Immuneering Corporation held its Annual Meeting of Stockholders on June 11, 2026, where shareholders elected Peter Feinberg and Laurie B. Keating as Class II directors and ratified RSM US LLP as the independent auditor for the 2026 fiscal year. This decision by 68.8% of outstandi", "url": "https://www.theglobeandmail.com/investing/markets/stocks/IMRX/pressreleases/2449289/immuneering-shareholders-approve-directors-and-auditor-at-meeting/", "source_name": "The Globe and Mail", "published_at": "2026-06-14T21:39:13", "published_display": "14 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering (IMRX) director receives 33,350 stock options at $4.12 strike", "summary": "Immuneering Corp (IMRX) director Thomas J. Schall was granted 33,350 stock options at an exercise price of $4.12 per share. This compensation-related equity grant vests in equal monthly installments over one year, starting July 11, 2026, and will be fully vested by June 11, 2027,", "url": "https://www.stocktitan.net/sec-filings/IMRX/form-4-immuneering-corp-insider-trading-activity-c5bf27f76a10.html", "source_name": "Stock Titan", "published_at": "2026-06-13T15:09:15", "published_display": "13 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering (IMRX) director Diana Hausman awarded 33,350 stock options at $4.12", "summary": "Immuneering Corp director Diana Hausman was granted 33,350 stock options with an exercise price of $4.12 per share as compensation. These options will vest in equal monthly installments over one year, starting July 11, 2026, and will be fully vested by June 11, 2027, or the date ", "url": "https://www.stocktitan.net/sec-filings/IMRX/form-4-immuneering-corp-insider-trading-activity-f3317d0397cf.html", "source_name": "Stock Titan", "published_at": "2026-06-13T02:40:34", "published_display": "13 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Corporation Files Form 8-K with SEC Detailing Company Information as of June 11, 2026", "summary": "Immuneering Corporation (NASDAQ: IMRX) has filed a Form 8-K with the SEC detailing the results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. Key outcomes included the election of Peter Feinberg and Laurie B. Keating as Class II directors and the ratification o", "url": "https://www.minichart.com.sg/2026/06/12/immuneering-corporation-files-form-8-k-with-sec-detailing-company-information-as-of-june-11-2026/", "source_name": "Minichart", "published_at": "2026-06-12T18:39:28", "published_display": "12 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering's Phase 3 Trial of Atebimetinib Plus mGnP to Treat Pancreatic Cancer Doses First Patient", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immuneering-apos-phase-3-trial-122414693.html", "source_name": "MT Newswires", "published_at": "2026-06-11T12:24:14+00:00", "published_display": "11 Jun 2026 12:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immuneering-announces-first-patient-dosed-113000961.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T11:30:00+00:00", "published_display": "11 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMRX - Immuneering Corp Stock Price and Quote", "summary": "This article provides a comprehensive overview of Immuneering Corp (IMRX) stock, including its latest closing price, financial metrics, valuation ratios, and stock performance. It also details recent analyst ratings with price targets and a chronological list of company news and ", "url": "https://finviz.com/stock?t=IMRX", "source_name": "Finviz", "published_at": "2026-06-03T02:14:37", "published_display": "03 Jun 2026 02:14", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Immuneering Corp Reports Material Event", "summary": "Immuneering Corporation announced updated Phase 2a results for its oral MEK inhibitor atebimetinib combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing a median overall survival of 17.3 months. The company plans to initiate a pivotal Phase 3 ", "url": "https://www.stocktitan.net/sec-filings/IMRX/8-k-immuneering-corp-reports-material-event-fb8ca68d8cc4.html", "source_name": "Stock Titan", "published_at": "2026-06-02T14:39:42", "published_display": "02 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immuneering-presents-compelling-17-3-113000365.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T11:30:00+00:00", "published_display": "01 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crude Oil Edges Higher; US Consumer Sentiment Falls In May", "summary": "U.S. stocks showed gains on Friday, with the Dow Jones index rising more than 400 points, despite a significant drop in the University of Michigan's consumer sentiment index to a record low of 44.8 in May. Several equities experienced substantial movements, with Immuneering Corp,", "url": "https://www.sahmcapital.com/news/content/crude-oil-edges-higher-us-consumer-sentiment-falls-in-may-2026-05-22", "source_name": "Sahm", "published_at": "2026-05-22T21:39:36", "published_display": "22 May 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immuneering-reports-17-3-months-210000614.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T21:00:00+00:00", "published_display": "21 May 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Corporation to Present Phase 2a Trial Results for Atebimetinib at ASCO Annual Meeting on June 1, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPUDdSeDc5SnE3ZDlFY1BrajNjWllHZFRydEN6YWJJUmsxTGx4bG4tX0c0M3pYVjJIS1N3dUJ5Uy1SclJnZmc4eXdQamo2V1JCbWxxR3ZTU09pOFBBcHplVTZBM3RIV0JZTDhpOXF0OUVpTDE4Rzd5eHFvUW9Da1hiQjIwVC1WUUQ0SUp2WHFUWV9xTEFrMmJ2MFZsMW1Ja0Y0V0lockRWZ293ZFExOUhWM25LdXNLUHM4WHE4UEYxWEVhN3FjcElqYnRfaW1xSFBNd1Qza3R6RjlxaFpUYmV5TnlB?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pancreatic data and cash runway into 2029 at Immuneering (NASDAQ: IMRX)", "summary": "Immuneering Corporation reported a Q1 2026 net loss of $13.5 million and ended the quarter with $198.6 million in cash, projecting a cash runway into 2029. The company highlighted significant progress in its oncology pipeline, including the recruitment for its pivotal Phase 3 MAP", "url": "https://www.stocktitan.net/sec-filings/IMRX/8-k-immuneering-corp-reports-material-event-4d346be993a7.html", "source_name": "Stock Titan", "published_at": "2026-05-16T06:09:51", "published_display": "16 May 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immuneering-reports-first-quarter-2026-113500888.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T11:35:00+00:00", "published_display": "15 May 2026 11:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immuneering\u2019s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors", "summary": "Immuneering Corp. (IMRX) is conducting a Phase 3 clinical trial, MAPKeeper 301, to evaluate its drug atebimetinib combined with chemotherapy as a first-line treatment for metastatic pancreatic cancer. The study, which began in April 2026 and was last updated on May 5, 2026, aims ", "url": "https://www.tipranks.com/news/company-announcements/immuneerings-phase-3-pancreatic-cancer-trial-puts-atebimetinib-in-the-spotlight-for-imrx-investors", "source_name": "TipRanks", "published_at": "2026-05-08T15:38:44", "published_display": "08 May 2026 15:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQYUhyN1lwVnUzdGt4Z1V2VEVTeUlFUFNLY0ducnhzWlJtT29HVHRKcjdNWnJNZ1FFS2t0dE5oQ2lkMEZuQWZwd3JzbVdwb0RpYVNrd2xTMGVySUJYM1QwclQ4aUNwdkRkUVJEZndGWVZmR1Qwa3NJN1NfNzcxRFk5YTRjT20wQnNkSGZIenRmR2YwMGcyR0paZ3lQQWI3dF9OMEkw?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Buyers At Immuneering Sitting On US$361k Profit", "summary": "Insiders at Immuneering Corporation, including the Chairman of the Board, purchased shares worth US$721,000 over the past year, which are now valued at US$1.08 million, indicating a profit despite a recent stock drop. This insider buying suggests confidence in the company, though", "url": "https://www.sahmcapital.com/news/content/insider-buyers-at-immuneering-sitting-on-us361k-profit-2026-05-02", "source_name": "Sahm", "published_at": "2026-05-02T13:08:53", "published_display": "02 May 2026 13:08", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immuneering (IMRX) details 2026 virtual meeting, director votes and auditor ratification", "summary": "Immuneering Corporation (IMRX) announced details for its virtual 2026 annual stockholder meeting, scheduled for June 11, 2026. Stockholders will vote on the election of two Class II directors, Peter Feinberg and Laurie B. Keating, for terms expiring in 2029, and the ratification ", "url": "https://www.stocktitan.net/sec-filings/IMRX/def-14a-immuneering-corp-definitive-proxy-statement-4a3b8df228c7.html", "source_name": "Stock Titan", "published_at": "2026-04-21T22:39:44", "published_display": "21 Apr 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering brings 55-patient pancreatic survival update to ASCO oral", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPcXR6aVhrM2t5TktQdWQ3QUxiT2Z2XzdyVmtjeUlFdWhYS1BZZDVJUURSWnBkMlM3YjRqdVI5c2VlTExwR0Q4UXJSM1BjVlJ3WlM0eEhkRUdGbTlWM1huZEQ5Q0l1M1NjMXQ5ZWRpWGxoQUdYMHFOejQ5aEh6NEcyYUFvaW1GU3FzMzd4c1lVOFFlT0JEYWpQMml3TGhOUEdJOWpBNmVNTC1YaHg0OGxYeGVueFE2VEs0OTYxSUtrbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Immuneering Corp (IMRX) CPO acquires shares through employee stock plan", "summary": "Immuneering Corp's Chief People Officer, Leah R. Neufeld, acquired 3,628 shares of Class A Common Stock on March 13, 2026, at $4.2925 per share through the company's 2021 Employee Stock Purchase Plan. This routine acquisition, part of an offering period from September 2025 to Mar", "url": "https://www.stocktitan.net/sec-filings/IMRX/form-4-immuneering-corp-insider-trading-activity-8d36d8ae0f7b.html", "source_name": "Stock Titan", "published_at": "2026-03-18T19:10:33", "published_display": "18 Mar 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: CAMP4 Therapeutics Corporation (CAMP), Owlet (OWLT) and Immuneering (IMRX)", "summary": "Three healthcare companies, CAMP4 Therapeutics Corporation (CAMP), Owlet (OWLT), and Immuneering (IMRX), recently received bullish sentiments from analysts. Wedbush reiterated a Buy rating on CAMP4 with an $8.00 price target, Lake Street maintained a Buy on Owlet with a $14.00 pr", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CAMP/pressreleases/624079/analysts-offer-insights-on-healthcare-companies-camp4-therapeutics-corporation-camp-owlet-owlt-and-immuneering-imrx/", "source_name": "The Globe and Mail", "published_at": "2026-03-11T18:09:20", "published_display": "11 Mar 2026 18:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering director Schall buys $101k in shares", "summary": "Immuneering Corp director Thomas J. Schall recently purchased 21,645 shares of Class A Common Stock for over $101,000. This insider transaction comes as Immuneering announced positive Phase 2a trial results for its pancreatic cancer drug, atebimetinib, and confirmed plans for a g", "url": "https://www.investing.com/news/insider-trading-news/immuneering-director-schall-buys-101k-in-shares-93CH-4455522", "source_name": "Investing.com", "published_at": "2026-02-11T01:51:52", "published_display": "11 Feb 2026 01:51", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "140,000 stock options granted to Immuneering Corp (IMRX) chief business officer", "summary": "Immuneering Corp's Chief Business Officer, Harold Eugene Brakewood, was granted 140,000 stock options on February 3, 2026, with an exercise price of $4.91 per share. These options will vest in equal monthly installments over four years, becoming fully exercisable by January 1, 20", "url": "https://www.stocktitan.net/sec-filings/IMRX/form-4-immuneering-corp-insider-trading-activity-668e9f380e87.html", "source_name": "Stock Titan", "published_at": "2026-02-05T16:40:16", "published_display": "05 Feb 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMRX Stock Price, News & Analysis", "summary": "Immuneering Corporation (IMRX) is a clinical-stage oncology company listed on Nasdaq, focused on developing Deep Cyclic Inhibitors (DCIs) for cancer treatment. Its lead product candidate, atebimetinib, targets MAPK pathway-driven tumors, including pancreatic cancer and NSCLC, and", "url": "https://www.stocktitan.net/overview/IMRX/", "source_name": "Stock Titan", "published_at": "2026-02-03T16:58:14", "published_display": "03 Feb 2026 16:58", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering\u2019s (IMRX) chief business officer buys $24,990 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQYWd6cjFwS2FZYVVQN0c3blFRaUlvX2FxQzZNakdXV0phaGtDSzRvTzZDcGYwZFpFQnJkenZyWkNhQkZTQ2FxNEx0T05XN0Q4WWZvYmE2T0gwa25OZ21Bd2FFbDFWYXA3WVhoZXhXd0liNS1uancyOTBIVGdIRzVzcnVyR2RoSmdkQUlCRTA1bVU0YlZXREV1bXhzbzc5R19laUxoOXFKRHVXNkFBZXJ2YXkxcDV5LWlqbmdaOG80OU85ejg?oc=5", "source_name": "Investing.com", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Director Acquires 1.8% More Stock", "summary": "Immuneering Corporation's Director, Peter Feinberg, recently purchased US$87k worth of stock at US$4.35 per share, increasing his shareholding by 1.8%. This follows a larger purchase by Chairman Thomas Schall 12 months ago at a lower price. Insiders collectively own 14% of the co", "url": "https://www.sahmcapital.com/news/content/immuneering-director-acquires-18-more-stock-2026-01-16", "source_name": "Sahm", "published_at": "2026-01-17T07:28:09", "published_display": "17 Jan 2026 07:28", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Looking Into Immuneering Corp's Recent Short Interest", "summary": "Immuneering Corp.'s short interest has significantly increased by 43.1% since its last report, now standing at 10.92 million shares, which represents 19.49% of its available trading shares. This elevated short interest is higher than the average for its peer group and suggests a ", "url": "https://www.sahmcapital.com/news/content/looking-into-immuneering-corps-recent-short-interest-2026-01-14", "source_name": "Sahm", "published_at": "2026-01-15T09:28:26", "published_display": "15 Jan 2026 09:28", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering director Feinberg buys $86k in shares By Investing.com", "summary": "Immuneering Corp Director Peter Feinberg purchased 20,000 shares of Class A Common Stock for $86,904 on January 12, 2026, increasing his direct and indirect holdings. This insider purchase occurs after a significant stock drop, though the company's valuation appears slightly unde", "url": "https://ng.investing.com/news/insider-trading-news/immuneering-director-feinberg-buys-86k-in-shares-93CH-2289479", "source_name": "Investing.com Nigeria", "published_at": "2026-01-14T19:57:37", "published_display": "14 Jan 2026 19:57", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering director Feinberg buys $86k in shares", "summary": "Immuneering Corp (NASDAQ:IMRX) Director Peter Feinberg purchased 20,000 shares of Class A Common Stock for $86,904 on January 12, 2026, increasing his direct and indirect holdings significantly. This insider transaction follows a recent stock drop of over 50% but the stock remain", "url": "https://m.investing.com/news/insider-trading-news/immuneering-director-feinberg-buys-86k-in-shares-93CH-4447187?ampMode=1", "source_name": "Investing.com", "published_at": "2026-01-14T12:57:44", "published_display": "14 Jan 2026 12:57", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQOXZFZDJGX3kxRnIzSVZLY2o2SWlEakRzZnFPdkZtOWhfTFhVN2R0d3hzQ0dGQnl6SFVRdnNOOE5lSk1uaWNtVTZsbzNVUlJDSjJ0UnRqazAxOTNQQVhZOWpqdkszbDdvY2w3Q1lDckZBVnVQSHRfUkxPbkpSRy04RHRpdDdNY3VkYnFQbWpB?oc=5", "source_name": "Market source", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's Next", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE11eVZ1VEJtT3VERGZoaUNYa0lLclZVVjhyVXhISTlFNnk1STJQZnVvYTJPbXY1b2lmOXM1cy1XQ3FkejF3aGg3cG9OcTlKUzZDNXgyVE1hd3RLWWp5UmxSZGRQS1I4ZkFWbXNOZExOVG1BRlVGSkV1bVVMVjhiZlU?oc=5", "source_name": "Market source", "published_at": "2026-01-10T08:00:00+00:00", "published_display": "10 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Immuneering (IMRX) Is Down 29.7% After Phase 2a Pancreatic Data Versus Historical Benchmarks And Phase 3 Plan", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-10T08:00:00+00:00", "published_display": "10 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Immuneering (IMRX) Valuation After Positive Phase 2a Pancreatic Cancer Trial Progress", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Institutional investors control 36% of Immuneering Corporation (NASDAQ:IMRX) and were rewarded last week after stock increased 19%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-27T08:00:00+00:00", "published_display": "27 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Immuneering (NASDAQ:IMRX) Can Afford To Drive Business Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQd1dhUmwzcFpsOVRIMWVYbVhZSWNCNDN4R1phOGNOX1lfOFJ3VjZPMHlwa1hXNUR5RVNlUUM2dEJxRzFKQmo1ZmpEWUhNbUFXQW5JaDIwNG9QbENaV0tfX2ZiNEFrX25UX3JIS205MmlKaWFCdGNFdzR3MHNhYUZVQzFKd2pLUWRtamc?oc=5", "source_name": "Market source", "published_at": "2025-11-27T08:00:00+00:00", "published_display": "27 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Immuneering Stock Soared Over 40% After-Hours Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOQ0FBcXdiMmUxR0J6Y1NfdXBUSUY1aVllelFuUVhfNXpnbGlWVnVhVGVMR0NLcUMtOTZBdGN0RjdZLXJNWk9KNGhIZ1pRYktQU2ppV1FZZ3otNzdNa2lLbkJvZ3RxRW1lRTdVbmVZZThtYkZXbUFjNVlGdGt1SjJZeUlZNGFNZ0t6SVNUQXpVTG9DV0MtcW5EdlhselF3MVJVV2lfTUJoLTlzcWxtWmxGX2VUM1dTdzl6cXc?oc=5", "source_name": "Stocktwits", "published_at": "2025-09-24T07:00:00+00:00", "published_display": "24 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Corporation Closes $25 Million Private Placement to Support Oncology Drug Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPTkdGX0NuLXhITnFfTThYeXVManBmWUxLRkI3T29MUi10bUlEOG5Ra25DdnJlZm9aeWZPNHBsaDlucGl1Uzg5OHBPUEVQMkwzcldHUnRvYWlCX3V6TExRNElfR2I3MF9XMTh3LVdHNjlidjFkc1dYNnlrNGFPYnFPRTJrN2Y0bzBNLWpiNFFjLWdLV3FWMnBZTTN1VkxaU0lWOEpCQkM4RDNPYTZVcVcyc1Jmb3JBMmxLR3hKRHFNcDFxRkpBa0JwQjZaN3c?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-08-26T07:00:00+00:00", "published_display": "26 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering (IMRX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1nZlJRbXg5NmJIaWdtRFRoVTZXTXRJMlBzZWJNbEZ6VUhNTFpxQzdlbnIwWkl0RzJVOXpodTU3eUtmUmxNVEdkYzZkYVB2R0Q4NERF?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:35:16+00:00", "published_display": "25 Apr 2025 00:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQQkhoUFlYd0FQSHh4ck9KaExvSkgycmtSVXpyaUU2LXJzanM1ZG4taER3LUFoaGFmN05XMlhJWTBIMkZXZ3JzTFlCTXpVUzhWLVFQeEl2OXN4S0dJRUthVll2UEFRdHF4Q0JoczN5QnB2VnlVaWhlNkdBeWdLOEd1aWp4TmxmV1prdzRJOE16dDRueTRlZFQyVTdkYXlnTnRhT3c?oc=5", "source_name": "Market source", "published_at": "2026-07-15T16:00:05+00:00", "published_display": "15 Jul 2026 16:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering (IMRX) Proxy filing Summary", "summary": "", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTE1feURjOWhkaUhLZlhZOV9qVXVzMDhsOG1TVHNxZVRBTV94UmlNOGVjb2VidVNWeFJwaWNWa3hGNnBjUWs0VnJzUTJkVWlMdl9VUEZ1aDhEdWszaEFoWnM4T2RqU1ZiN1pzaDhaMmV3OE9Pdw?oc=5", "source_name": "Quartr", "published_at": "2026-07-13T21:58:40+00:00", "published_display": "13 Jul 2026 21:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Immuneering Corporation \u2013 NASDAQ:IMRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNVU9sRUJTTWFkOEdPTldiaFNCOWthVHhBdVdTQmM1YjV4cW1VQjktWDVyWTN0b1JlcTctbHdMdWxxX19zWTNTbTJqT084Wk56UWFJbUY0WWRPOGdVU0E3enN0UTliaDZjUGJvOHRSTkVrOGtTWDBoSDZtUEtQeVFLd2ljRmtCOUFFVDM3bzVtTnlSQnA4bnFRM0pxX01ETXVpQVE?oc=5", "source_name": "TradingView", "published_at": "2026-07-12T19:02:53+00:00", "published_display": "12 Jul 2026 19:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth", "summary": "Immuneering (NASDAQ:IMRX) is an unprofitable company with a strong cash runway of over three years, possessing US$157m in cash against an annual burn of US$50m as of March 2026. The company has reduced its cash burn by 7% over the last year, indicating steady business development", "url": "https://www.sahmcapital.com/news/content/companies-like-immuneering-nasdaqimrx-are-in-a-position-to-invest-in-growth-2026-06-30", "source_name": "Sahm", "published_at": "2026-06-30T15:41:43", "published_display": "30 Jun 2026 15:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Corp. Class A Actuals & Estimates (NASDAQ:IMRX)", "summary": "Immuneering Corporation's stock (IMRX) is currently trading at $4.53, having decreased slightly in the past 24 hours but showing a 57.29% increase over the last year. Analysts have a wide price target range for IMRX, with a maximum estimate of $30.00 and a minimum of $11.00. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-IMRX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:10:51", "published_display": "26 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering CEO Zeskind buys $10,948 in stock By Investing.com", "summary": "Immuneering Corp (NASDAQ:IMRX) CEO Benjamin J. Zeskind recently purchased 2,400 shares of the company's stock for a total of $10,948, bringing his direct holdings to over 2.3 million shares. This insider purchase occurs as the stock trades near $4.60, up significantly over the pa", "url": "https://ca.investing.com/news/stock-market-news/immuneering-ceo-zeskind-buys-10948-in-stock-93CH-4706573", "source_name": "Investing.com Canada", "published_at": "2026-06-25T13:09:32", "published_display": "25 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering CEO Zeskind buys $10,948 in stock", "summary": "Immuneering Corp's CEO, Benjamin J. Zeskind, purchased 2,400 shares of the company's Class A Common Stock for $10,948 on June 23, 2026. This insider transaction comes as the stock trades near $4.60, with InvestingPro analysis suggesting it is undervalued. The company also announc", "url": "https://m.uk.investing.com/news/stock-market-news/immuneering-ceo-zeskind-buys-10948-in-stock-93CH-4743544?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-25T11:10:51", "published_display": "25 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering CEO buys 2,400 shares in open market | IMRX Insider Trading", "summary": "Immuneering Corp. CEO Benjamin J. Zeskind purchased 2,400 shares of Class A Common Stock in an open-market transaction on June 23, 2026, at a weighted average price of $4.5617 per share. This transaction increases his direct holdings to 2,315,252 shares, with an additional 894,92", "url": "https://www.stocktitan.net/sec-filings/IMRX/form-4-immuneering-corp-insider-trading-activity-930bc27b220a.html", "source_name": "Stock Titan", "published_at": "2026-06-25T01:39:31", "published_display": "25 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering (IMRX) CEO buys 2,400 shares in open-market trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOSm9NcS1sOG9zMGhIU1VZcno0MkE1ck5VQWdYSWpaZ0VFVVJ0RnZ2bTJjcGVqZWRoTUd6WGZYVkIyOXYwcHNMY21tNWNOOWNfUzFNVkRYYWY0MzlmR0xoRm0wLUtWREJJSmQ0TC16cFJJSFVNVWdCNDM4bHUzZVhYX0c5dy1LTXhhNDk2TWpyclRmUF96b3FpTE9JU3N5WmY5TDRCeG9YR0ZJTTdKNEQ4?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering (NASDAQ: IMRX) CSO purchases 6,035 shares in open-market trade", "summary": "Immuneering Corp's Chief Scientific Officer, Brett Matthew Hall, purchased 6,035 shares of Class A Common Stock on June 15, 2026, at a weighted average price of $4.15 per share. This open-market transaction increased his direct holdings to 382,531 shares. The trade was executed t", "url": "https://www.stocktitan.net/sec-filings/IMRX/form-4-immuneering-corp-insider-trading-activity-771fda215c13.html", "source_name": "Stock Titan", "published_at": "2026-06-17T04:39:24", "published_display": "17 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New CFO Andrew Gengos joins Immuneering (NASDAQ: IMRX) with equity grant", "summary": "Immuneering Corporation has appointed Andrew Gengos as its new Chief Financial Officer, Treasurer, and principal financial officer, effective on or before July 16, 2026. He will receive an annual base salary of $530,000, a target annual bonus of 40% of his base salary, and an opt", "url": "https://www.stocktitan.net/sec-filings/IMRX/8-k-immuneering-corp-reports-material-event-5784889e26cb.html", "source_name": "Stock Titan", "published_at": "2026-06-16T08:39:17", "published_display": "16 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Names Andrew Gengos as CFO", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immuneering-names-andrew-gengos-cfo-125828979.html", "source_name": "MT Newswires", "published_at": "2026-06-15T12:58:28+00:00", "published_display": "15 Jun 2026 12:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Appoints Andrew Gengos as Chief Financial Officer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immuneering-appoints-andrew-gengos-chief-113000153.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T11:30:00+00:00", "published_display": "15 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Andrew Gengos joins Immuneering as new chief financial officer", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOWTZUM2lUTmFqbWRBemVSUUNuR1QwcG1DdmhGYkxZVzhaZ2lsdHhSYkxSSGZ6QXNqbkx1N3EwNDVOQ1NLZFppSG1uV3N6S3pPRU91bk9sSXlVR3FzaV94bXA4RnFmbG83Q282T0p1WV8wYkZPdm1lcktvcjg0S0l1Wg?oc=5", "source_name": "Traders Union", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Shareholders Approve Directors and Auditor at Meeting", "summary": "Immuneering Corporation held its Annual Meeting of Stockholders on June 11, 2026, where shareholders elected Peter Feinberg and Laurie B. Keating as Class II directors and ratified RSM US LLP as the independent auditor for the 2026 fiscal year. This decision by 68.8% of outstandi", "url": "https://www.theglobeandmail.com/investing/markets/stocks/IMRX/pressreleases/2449289/immuneering-shareholders-approve-directors-and-auditor-at-meeting/", "source_name": "The Globe and Mail", "published_at": "2026-06-14T21:39:13", "published_display": "14 Jun 2026 21:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering (IMRX) director receives 33,350 stock options at $4.12 strike", "summary": "Immuneering Corp (IMRX) director Thomas J. Schall was granted 33,350 stock options at an exercise price of $4.12 per share. This compensation-related equity grant vests in equal monthly installments over one year, starting July 11, 2026, and will be fully vested by June 11, 2027,", "url": "https://www.stocktitan.net/sec-filings/IMRX/form-4-immuneering-corp-insider-trading-activity-c5bf27f76a10.html", "source_name": "Stock Titan", "published_at": "2026-06-13T15:09:15", "published_display": "13 Jun 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering (IMRX) director Diana Hausman awarded 33,350 stock options at $4.12", "summary": "Immuneering Corp director Diana Hausman was granted 33,350 stock options with an exercise price of $4.12 per share as compensation. These options will vest in equal monthly installments over one year, starting July 11, 2026, and will be fully vested by June 11, 2027, or the date ", "url": "https://www.stocktitan.net/sec-filings/IMRX/form-4-immuneering-corp-insider-trading-activity-f3317d0397cf.html", "source_name": "Stock Titan", "published_at": "2026-06-13T02:40:34", "published_display": "13 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Corporation Files Form 8-K with SEC Detailing Company Information as of June 11, 2026", "summary": "Immuneering Corporation (NASDAQ: IMRX) has filed a Form 8-K with the SEC detailing the results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. Key outcomes included the election of Peter Feinberg and Laurie B. Keating as Class II directors and the ratification o", "url": "https://www.minichart.com.sg/2026/06/12/immuneering-corporation-files-form-8-k-with-sec-detailing-company-information-as-of-june-11-2026/", "source_name": "Minichart", "published_at": "2026-06-12T18:39:28", "published_display": "12 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering's Phase 3 Trial of Atebimetinib Plus mGnP to Treat Pancreatic Cancer Doses First Patient", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immuneering-apos-phase-3-trial-122414693.html", "source_name": "MT Newswires", "published_at": "2026-06-11T12:24:14+00:00", "published_display": "11 Jun 2026 12:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immuneering-announces-first-patient-dosed-113000961.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T11:30:00+00:00", "published_display": "11 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMRX - Immuneering Corp Stock Price and Quote", "summary": "This article provides a comprehensive overview of Immuneering Corp (IMRX) stock, including its latest closing price, financial metrics, valuation ratios, and stock performance. It also details recent analyst ratings with price targets and a chronological list of company news and ", "url": "https://finviz.com/stock?t=IMRX", "source_name": "Finviz", "published_at": "2026-06-03T02:14:37", "published_display": "03 Jun 2026 02:14", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Immuneering Corp Reports Material Event", "summary": "Immuneering Corporation announced updated Phase 2a results for its oral MEK inhibitor atebimetinib combined with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing a median overall survival of 17.3 months. The company plans to initiate a pivotal Phase 3 ", "url": "https://www.stocktitan.net/sec-filings/IMRX/8-k-immuneering-corp-reports-material-event-fb8ca68d8cc4.html", "source_name": "Stock Titan", "published_at": "2026-06-02T14:39:42", "published_display": "02 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immuneering-presents-compelling-17-3-113000365.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T11:30:00+00:00", "published_display": "01 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Crude Oil Edges Higher; US Consumer Sentiment Falls In May", "summary": "U.S. stocks showed gains on Friday, with the Dow Jones index rising more than 400 points, despite a significant drop in the University of Michigan's consumer sentiment index to a record low of 44.8 in May. Several equities experienced substantial movements, with Immuneering Corp,", "url": "https://www.sahmcapital.com/news/content/crude-oil-edges-higher-us-consumer-sentiment-falls-in-may-2026-05-22", "source_name": "Sahm", "published_at": "2026-05-22T21:39:36", "published_display": "22 May 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immuneering-reports-17-3-months-210000614.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T21:00:00+00:00", "published_display": "21 May 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Corporation to Present Phase 2a Trial Results for Atebimetinib at ASCO Annual Meeting on June 1, 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPUDdSeDc5SnE3ZDlFY1BrajNjWllHZFRydEN6YWJJUmsxTGx4bG4tX0c0M3pYVjJIS1N3dUJ5Uy1SclJnZmc4eXdQamo2V1JCbWxxR3ZTU09pOFBBcHplVTZBM3RIV0JZTDhpOXF0OUVpTDE4Rzd5eHFvUW9Da1hiQjIwVC1WUUQ0SUp2WHFUWV9xTEFrMmJ2MFZsMW1Ja0Y0V0lockRWZ293ZFExOUhWM25LdXNLUHM4WHE4UEYxWEVhN3FjcElqYnRfaW1xSFBNd1Qza3R6RjlxaFpUYmV5TnlB?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pancreatic data and cash runway into 2029 at Immuneering (NASDAQ: IMRX)", "summary": "Immuneering Corporation reported a Q1 2026 net loss of $13.5 million and ended the quarter with $198.6 million in cash, projecting a cash runway into 2029. The company highlighted significant progress in its oncology pipeline, including the recruitment for its pivotal Phase 3 MAP", "url": "https://www.stocktitan.net/sec-filings/IMRX/8-k-immuneering-corp-reports-material-event-4d346be993a7.html", "source_name": "Stock Titan", "published_at": "2026-05-16T06:09:51", "published_display": "16 May 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immuneering-reports-first-quarter-2026-113500888.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T11:35:00+00:00", "published_display": "15 May 2026 11:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering\u2019s Phase 3 Pancreatic Cancer Trial Puts Atebimetinib in the Spotlight for IMRX Investors", "summary": "Immuneering Corp. (IMRX) is conducting a Phase 3 clinical trial, MAPKeeper 301, to evaluate its drug atebimetinib combined with chemotherapy as a first-line treatment for metastatic pancreatic cancer. The study, which began in April 2026 and was last updated on May 5, 2026, aims ", "url": "https://www.tipranks.com/news/company-announcements/immuneerings-phase-3-pancreatic-cancer-trial-puts-atebimetinib-in-the-spotlight-for-imrx-investors", "source_name": "TipRanks", "published_at": "2026-05-08T15:38:44", "published_display": "08 May 2026 15:38", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQYUhyN1lwVnUzdGt4Z1V2VEVTeUlFUFNLY0ducnhzWlJtT29HVHRKcjdNWnJNZ1FFS2t0dE5oQ2lkMEZuQWZwd3JzbVdwb0RpYVNrd2xTMGVySUJYM1QwclQ4aUNwdkRkUVJEZndGWVZmR1Qwa3NJN1NfNzcxRFk5YTRjT20wQnNkSGZIenRmR2YwMGcyR0paZ3lQQWI3dF9OMEkw?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Buyers At Immuneering Sitting On US$361k Profit", "summary": "Insiders at Immuneering Corporation, including the Chairman of the Board, purchased shares worth US$721,000 over the past year, which are now valued at US$1.08 million, indicating a profit despite a recent stock drop. This insider buying suggests confidence in the company, though", "url": "https://www.sahmcapital.com/news/content/insider-buyers-at-immuneering-sitting-on-us361k-profit-2026-05-02", "source_name": "Sahm", "published_at": "2026-05-02T13:08:53", "published_display": "02 May 2026 13:08", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering (IMRX) details 2026 virtual meeting, director votes and auditor ratification", "summary": "Immuneering Corporation (IMRX) announced details for its virtual 2026 annual stockholder meeting, scheduled for June 11, 2026. Stockholders will vote on the election of two Class II directors, Peter Feinberg and Laurie B. Keating, for terms expiring in 2029, and the ratification ", "url": "https://www.stocktitan.net/sec-filings/IMRX/def-14a-immuneering-corp-definitive-proxy-statement-4a3b8df228c7.html", "source_name": "Stock Titan", "published_at": "2026-04-21T22:39:44", "published_display": "21 Apr 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering brings 55-patient pancreatic survival update to ASCO oral", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPcXR6aVhrM2t5TktQdWQ3QUxiT2Z2XzdyVmtjeUlFdWhYS1BZZDVJUURSWnBkMlM3YjRqdVI5c2VlTExwR0Q4UXJSM1BjVlJ3WlM0eEhkRUdGbTlWM1huZEQ5Q0l1M1NjMXQ5ZWRpWGxoQUdYMHFOejQ5aEh6NEcyYUFvaW1GU3FzMzd4c1lVOFFlT0JEYWpQMml3TGhOUEdJOWpBNmVNTC1YaHg0OGxYeGVueFE2VEs0OTYxSUtrbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Corp (IMRX) CPO acquires shares through employee stock plan", "summary": "Immuneering Corp's Chief People Officer, Leah R. Neufeld, acquired 3,628 shares of Class A Common Stock on March 13, 2026, at $4.2925 per share through the company's 2021 Employee Stock Purchase Plan. This routine acquisition, part of an offering period from September 2025 to Mar", "url": "https://www.stocktitan.net/sec-filings/IMRX/form-4-immuneering-corp-insider-trading-activity-8d36d8ae0f7b.html", "source_name": "Stock Titan", "published_at": "2026-03-18T19:10:33", "published_display": "18 Mar 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: CAMP4 Therapeutics Corporation (CAMP), Owlet (OWLT) and Immuneering (IMRX)", "summary": "Three healthcare companies, CAMP4 Therapeutics Corporation (CAMP), Owlet (OWLT), and Immuneering (IMRX), recently received bullish sentiments from analysts. Wedbush reiterated a Buy rating on CAMP4 with an $8.00 price target, Lake Street maintained a Buy on Owlet with a $14.00 pr", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CAMP/pressreleases/624079/analysts-offer-insights-on-healthcare-companies-camp4-therapeutics-corporation-camp-owlet-owlt-and-immuneering-imrx/", "source_name": "The Globe and Mail", "published_at": "2026-03-11T18:09:20", "published_display": "11 Mar 2026 18:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering director Schall buys $101k in shares", "summary": "Immuneering Corp director Thomas J. Schall recently purchased 21,645 shares of Class A Common Stock for over $101,000. This insider transaction comes as Immuneering announced positive Phase 2a trial results for its pancreatic cancer drug, atebimetinib, and confirmed plans for a g", "url": "https://www.investing.com/news/insider-trading-news/immuneering-director-schall-buys-101k-in-shares-93CH-4455522", "source_name": "Investing.com", "published_at": "2026-02-11T01:51:52", "published_display": "11 Feb 2026 01:51", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "140,000 stock options granted to Immuneering Corp (IMRX) chief business officer", "summary": "Immuneering Corp's Chief Business Officer, Harold Eugene Brakewood, was granted 140,000 stock options on February 3, 2026, with an exercise price of $4.91 per share. These options will vest in equal monthly installments over four years, becoming fully exercisable by January 1, 20", "url": "https://www.stocktitan.net/sec-filings/IMRX/form-4-immuneering-corp-insider-trading-activity-668e9f380e87.html", "source_name": "Stock Titan", "published_at": "2026-02-05T16:40:16", "published_display": "05 Feb 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IMRX Stock Price, News & Analysis", "summary": "Immuneering Corporation (IMRX) is a clinical-stage oncology company listed on Nasdaq, focused on developing Deep Cyclic Inhibitors (DCIs) for cancer treatment. Its lead product candidate, atebimetinib, targets MAPK pathway-driven tumors, including pancreatic cancer and NSCLC, and", "url": "https://www.stocktitan.net/overview/IMRX/", "source_name": "Stock Titan", "published_at": "2026-02-03T16:58:14", "published_display": "03 Feb 2026 16:58", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering\u2019s (IMRX) chief business officer buys $24,990 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxQYWd6cjFwS2FZYVVQN0c3blFRaUlvX2FxQzZNakdXV0phaGtDSzRvTzZDcGYwZFpFQnJkenZyWkNhQkZTQ2FxNEx0T05XN0Q4WWZvYmE2T0gwa25OZ21Bd2FFbDFWYXA3WVhoZXhXd0liNS1uancyOTBIVGdIRzVzcnVyR2RoSmdkQUlCRTA1bVU0YlZXREV1bXhzbzc5R19laUxoOXFKRHVXNkFBZXJ2YXkxcDV5LWlqbmdaOG80OU85ejg?oc=5", "source_name": "Investing.com", "published_at": "2026-01-21T08:00:00+00:00", "published_display": "21 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Director Acquires 1.8% More Stock", "summary": "Immuneering Corporation's Director, Peter Feinberg, recently purchased US$87k worth of stock at US$4.35 per share, increasing his shareholding by 1.8%. This follows a larger purchase by Chairman Thomas Schall 12 months ago at a lower price. Insiders collectively own 14% of the co", "url": "https://www.sahmcapital.com/news/content/immuneering-director-acquires-18-more-stock-2026-01-16", "source_name": "Sahm", "published_at": "2026-01-17T07:28:09", "published_display": "17 Jan 2026 07:28", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Looking Into Immuneering Corp's Recent Short Interest", "summary": "Immuneering Corp.'s short interest has significantly increased by 43.1% since its last report, now standing at 10.92 million shares, which represents 19.49% of its available trading shares. This elevated short interest is higher than the average for its peer group and suggests a ", "url": "https://www.sahmcapital.com/news/content/looking-into-immuneering-corps-recent-short-interest-2026-01-14", "source_name": "Sahm", "published_at": "2026-01-15T09:28:26", "published_display": "15 Jan 2026 09:28", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering director Feinberg buys $86k in shares By Investing.com", "summary": "Immuneering Corp Director Peter Feinberg purchased 20,000 shares of Class A Common Stock for $86,904 on January 12, 2026, increasing his direct and indirect holdings. This insider purchase occurs after a significant stock drop, though the company's valuation appears slightly unde", "url": "https://ng.investing.com/news/insider-trading-news/immuneering-director-feinberg-buys-86k-in-shares-93CH-2289479", "source_name": "Investing.com Nigeria", "published_at": "2026-01-14T19:57:37", "published_display": "14 Jan 2026 19:57", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering director Feinberg buys $86k in shares", "summary": "Immuneering Corp (NASDAQ:IMRX) Director Peter Feinberg purchased 20,000 shares of Class A Common Stock for $86,904 on January 12, 2026, increasing his direct and indirect holdings significantly. This insider transaction follows a recent stock drop of over 50% but the stock remain", "url": "https://m.investing.com/news/insider-trading-news/immuneering-director-feinberg-buys-86k-in-shares-93CH-4447187?ampMode=1", "source_name": "Investing.com", "published_at": "2026-01-14T12:57:44", "published_display": "14 Jan 2026 12:57", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering (IMRX) Valuation After Strong Phase 2a Pancreatic Cancer Data And Planned Phase 3 Transition", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQOXZFZDJGX3kxRnIzSVZLY2o2SWlEakRzZnFPdkZtOWhfTFhVN2R0d3hzQ0dGQnl6SFVRdnNOOE5lSk1uaWNtVTZsbzNVUlJDSjJ0UnRqazAxOTNQQVhZOWpqdkszbDdvY2w3Q1lDckZBVnVQSHRfUkxPbkpSRy04RHRpdDdNY3VkYnFQbWpB?oc=5", "source_name": "Market source", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Immuneering (IMRX) Is Down 29.7% After Positive Phase 2a Pancreatic Cancer Survival Update And What's Next", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE11eVZ1VEJtT3VERGZoaUNYa0lLclZVVjhyVXhISTlFNnk1STJQZnVvYTJPbXY1b2lmOXM1cy1XQ3FkejF3aGg3cG9OcTlKUzZDNXgyVE1hd3RLWWp5UmxSZGRQS1I4ZkFWbXNOZExOVG1BRlVGSkV1bVVMVjhiZlU?oc=5", "source_name": "Market source", "published_at": "2026-01-10T08:00:00+00:00", "published_display": "10 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Immuneering (IMRX) Is Down 29.7% After Phase 2a Pancreatic Data Versus Historical Benchmarks And Phase 3 Plan", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-10T08:00:00+00:00", "published_display": "10 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Immuneering (IMRX) Valuation After Positive Phase 2a Pancreatic Cancer Trial Progress", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Institutional investors control 36% of Immuneering Corporation (NASDAQ:IMRX) and were rewarded last week after stock increased 19%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-27T08:00:00+00:00", "published_display": "27 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Immuneering (NASDAQ:IMRX) Can Afford To Drive Business Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxQd1dhUmwzcFpsOVRIMWVYbVhZSWNCNDN4R1phOGNOX1lfOFJ3VjZPMHlwa1hXNUR5RVNlUUM2dEJxRzFKQmo1ZmpEWUhNbUFXQW5JaDIwNG9QbENaV0tfX2ZiNEFrX25UX3JIS205MmlKaWFCdGNFdzR3MHNhYUZVQzFKd2pLUWRtamc?oc=5", "source_name": "Market source", "published_at": "2025-11-27T08:00:00+00:00", "published_display": "27 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Immuneering Stock Soared Over 40% After-Hours Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOQ0FBcXdiMmUxR0J6Y1NfdXBUSUY1aVllelFuUVhfNXpnbGlWVnVhVGVMR0NLcUMtOTZBdGN0RjdZLXJNWk9KNGhIZ1pRYktQU2ppV1FZZ3otNzdNa2lLbkJvZ3RxRW1lRTdVbmVZZThtYkZXbUFjNVlGdGt1SjJZeUlZNGFNZ0t6SVNUQXpVTG9DV0MtcW5EdlhselF3MVJVV2lfTUJoLTlzcWxtWmxGX2VUM1dTdzl6cXc?oc=5", "source_name": "Stocktwits", "published_at": "2025-09-24T07:00:00+00:00", "published_display": "24 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering Corporation Closes $25 Million Private Placement to Support Oncology Drug Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPTkdGX0NuLXhITnFfTThYeXVManBmWUxLRkI3T29MUi10bUlEOG5Ra25DdnJlZm9aeWZPNHBsaDlucGl1Uzg5OHBPUEVQMkwzcldHUnRvYWlCX3V6TExRNElfR2I3MF9XMTh3LVdHNjlidjFkc1dYNnlrNGFPYnFPRTJrN2Y0bzBNLWpiNFFjLWdLV3FWMnBZTTN1VkxaU0lWOEpCQkM4RDNPYTZVcVcyc1Jmb3JBMmxLR3hKRHFNcDFxRkpBa0JwQjZaN3c?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-08-26T07:00:00+00:00", "published_display": "26 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immuneering (IMRX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE1nZlJRbXg5NmJIaWdtRFRoVTZXTXRJMlBzZWJNbEZ6VUhNTFpxQzdlbnIwWkl0RzJVOXpodTU3eUtmUmxNVEdkYzZkYVB2R0Q4NERF?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:35:16+00:00", "published_display": "25 Apr 2025 00:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 60, "sentiment_summary": {"positive": 23, "negative": 2, "neutral": 35, "score": 59, "total": 60, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 19.8, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 7.7, "count": 16}, {"event": "analyst", "label": "Analyst action", "weight": 2.75, "count": 5}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 23, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 5.11, "latest_week": "2026-07-10", "one_week_move": -1.5, "four_week_move": 22.0, "twelve_week_move": -8.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.503306, "market_dynamics_buy_signal": false, "relative_strength": -21.114923, "fair_value_gap": 19.7, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 47.9648, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.5% over one week, +22.0% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 70, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 14}, {"label": "Market source", "count": 10}, {"label": "Sahm", "count": 5}, {"label": "GlobeNewswire", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "Investing.com", "count": 4}, {"label": "TradingView", "count": 3}, {"label": "MT Newswires", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 16}, {"label": "Analyst action", "count": 5}, {"label": "Balance sheet", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.5% over one week, +22.0% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know"}], "updated_at": "2026-07-16T06:04:34.006318+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}